Aptose Biosciences is a clinical-stage biotechnology company developing precision medicines for hematologic oncology. Its lead asset, tuspetinib, is an oral once-daily kinase inhibitor being investigated for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes. The company is advancing tuspetinib in the Phase 1/2 TUSCANY trial as a triplet combination (TUS+VEN+AZA) for newly diagnosed AML. Aptose is headquartered in San Diego, CA, with a head office in Toronto, Canada.
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-135012 | EDGAR | 80K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046366 | EDGAR | 77K words |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036537 | EDGAR | 55K words |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009560 | EDGAR | 49K words |
| 2022-03-22 | 2021-12-31 | 0001171843-22-002048 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001171843-21-002006 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001171843-20-001617 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001171843-19-001661 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280433 | EDGAR | 29K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108110 | EDGAR | 28K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066391 | EDGAR | 25K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124343 | EDGAR | 27K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094205 | EDGAR | 26K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059768 | EDGAR | 22K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062207 | EDGAR | 22K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041441 | EDGAR | 21K words |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018923 | EDGAR | 17K words |
| 2022-11-01 | 2022-09-30 | 0001171843-22-006964 | EDGAR | 23K words |
| 2022-08-02 | 2022-06-30 | 0001171843-22-005260 | EDGAR | 23K words |
| 2022-05-09 | 2022-03-31 | 0001171843-22-003463 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001171843-26-002103 | EDGAR | 3K words |
| 2026-03-31 | 0001193125-26-134870 | EDGAR | 1K words |
| 2026-03-23 | 0001193125-26-119951 | EDGAR | 1K words |
| 2026-03-23 | 0001171843-26-001837 | EDGAR | 1K words |
| 2026-03-19 | 0001171843-26-001777 | EDGAR | 1K words |
| 2026-02-24 | 0001193125-26-064847 | EDGAR | 2K words |
| 2025-12-19 | 0001171843-25-008045 | EDGAR | 1K words |
| 2025-12-08 | 0001171843-25-007795 | EDGAR | 1K words |
| 2025-11-25 | 0001193125-25-294108 | EDGAR | 67K words |
| 2025-11-19 | 0001171843-25-007415 | EDGAR | 3K words |
681 total filings indexed. 651 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000882361 |
| Ticker | APTOF |
| Exchange | OTC |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | A6 |
| Headquarters | San Diego, California |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APTOF (~200 tokens, structured JSON with cryptographic provenance)